Oral heparin using SNAC delivery agent: Phase I data; Phase II ongoing

Data from three Phase I trials published in Circulation showed significant elevation in four indices of anticoagulation in healthy volunteers, demonstrating the feasibility of oral heparin delivery. Dosing with 30,000 IU heparin plus 10.5 g SNAC elevated concentration of tissue factor pathway inhibitor (p<0.001) an hour after dosing, and similar changes occurred in anti- factor IIa and anti- factor Xa. Two hours after dosing, the activated partial thromboplastin time increased as well (p<0.01). Neither agent alone changed hemostatic parameters. The carrier agent did cause vomiting. ...